Clinical trials: BPH (Benign Prostatic Hyperplasia)
Prostatic Hyperplasia
SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
Primary Objective: To assess the sexual function improvement from baseline to the end of treatment (Week 24 or premature withdrawal (PW)) with XATRAL 10mg OD.
- Trial name
- NCT00486785
- Testing
- Alfuzosin
- Where
- 4 sites in Colombia, Ecuador and 2 more
- Volunteers
- 431 people
- Sponsor
- Sanofi
Erectile Dysfunction, Benign Prostatic Hyperplasia
Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin
We investigate the potential pharmacokinetic drug-drug interaction between Tadalafil and Tamsulosin in healthy male volunteers who receive Tadalafil alone, Tamsulosin alone, and both together in a 3 period repeatedly.
- Trial name
- NCT02239484
- Testing
- Tadalafil, Tamsulosin, Tadalafil + Tamsulosin
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia)
Sonablate HIFU International Registry for PC & BPH Patients
The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system.
- Conditions
- Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia), Prostate Cancer; Benign Prostatic Hyperplasia
- Trial name
- SONAFUSION (NCT07757490)
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Sonablate
Benign Prostatic Hyperplasia
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System.
- Trial name
- PEAK (NCT06312722)
- Testing
- Optilume® BPH Catheter System
- Where
- 7 sites in United States
- Volunteers
- 92 people
- Sponsor
- Urotronic Inc.
Prostate
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.
- Trial name
- NCT00648323
- Testing
- Doxazosin mysylate GITS
- Where
- 4 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prostatic Hyperplasia
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.
- Trial name
- NCT00408954
- Testing
- UK-369,003
- Where
- 11 sites in Czechia, Netherlands and 1 more
- Volunteers
- 27 people
- Sponsor
- Pfizer
Erectile Dysfunction, Benign Prostatic Hyperplasia
A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and 5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia…
- Trial name
- COMORBID© (NCT00855582)
- Testing
- Tadalafil
- Where
- 52 sites in United States, Canada and 7 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia, Prostate Cancer
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
Dutasteride is used in the treatment of benign prostate enlargement (BPH).It inhibits conversion of testosterone (T) into the more potent dihydrotestosterone (DHT) to stop prostate (and possibly prostate cancer) growth.
- Trial name
- NCT00375765
- Testing
- Dutasteride
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia (BPH)
China Greenlight Registry Study (Post-market)
The duration of the study is expected to take approximately 3 years, which includes a recruitment period of approximately 12-months and 2 years (24-months) to complete procedure and follow-up visits.
- Trial name
- NCT03736512
- Testing
- GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).
- Trial name
- RELIEF (NCT07640776)
- Testing
- Irreversible Electroporation
- Volunteers
- 40 people
- Sponsor
- Angiodynamics, Inc.
BPH, Benign Prostatic Hyperplasia
An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
In this study, BPH patients visited the institutions during the study period and the effectiveness and safety of the treatment of Tamsulosin(Hanmi Tams® Capsule) in real-practice.
- Trial name
- NCT05422677
- Testing
- Hanmi Tams® Capsule
- Where
- South Korea
- Volunteers
- 4,698 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Benign Prostatic Hyperplasia
A Study to Assess the Effect of Fucoidan on Prostate Health in Males With Benign Prostatic Hyperplasia
The present study is a randomized, double-blind, placebo-controlled study. Approximately 125 individuals will be screened, and considering a screening failure rate of 20%, at least 100 will be randomized in a ratio of 1:1 to…
- Trial name
- NCT06487871
- Testing
- Fucoidan extracted from Undaria pinnatifida (UPF)
- Where
- 6 sites in India
- Volunteers
- 95 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Benign Prostatic Hyperplasia
Temperature Mapping of the Prostate With the Wallterm™ System
To measure intra-prostatic temperatures and evaluate the shape and size of necrotic lesions achieved under the standard treatment protocol in men with benign prostatic hyperplasia (BPH).
- Trial name
- WT-DK-TMW08 (NCT00662350)
- Testing
- The Wallterm™ System
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Pnn Medical A/S
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Benign Prostatic Hyperplasia, Enlarged Prostate
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
- Trial name
- NCT00435448
- Testing
- Lonidamine
- Where
- 58 sites in Germany, Hungary and 2 more
- Volunteers
- 480 people
- Sponsor
- Threshold Pharmaceuticals
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVIDE Studies Post Exit Analysis
A study to collect data on the post-study exit incidence of secondary reintervention using alternate surgical LUTS therapy.
- Trial name
- NCT07680543
- Testing
- ProVee Urethral Expander System
- Volunteers
- 25 people
- Sponsor
- ProVerum Medical
Benign Prostatic Hyperplasia
A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia
This is a prospective, multicentre, non-interventional study, conducted in France and Spain, in primary care practices and designed to assess the QoL of patients under phytotherapy or alpha-blockers for LUTS/BPH.
- Trial name
- PERQoL (NCT07144709)
- Testing
- Phytotherapy
- Where
- 31 sites in France, Spain
- Volunteers
- 288 people
- Sponsor
- Pierre Fabre Medicament
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.
- Trial name
- MCS-2-US-c (NCT01002222)
- Testing
- MCS-2
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
A dual-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with catheters along with the use or absence of a hemostatic agent following treatment with the AQUABEAM System.
- Trial name
- AHAIII (NCT04308070)
- Testing
- AQUABEAM System followed by catheter without hemostatic agent, AQUABEAM System followed by catheter with hemostatic agent
- Where
- India
- Volunteers
- 26 people
- Sponsor
- PROCEPT BioRobotics